Edition:
United States

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

4.70USD
2:09pm EST
Change (% chg)

$-0.05 (-1.05%)
Prev Close
$4.75
Open
$4.80
Day's High
$4.95
Day's Low
$4.55
Volume
43,846
Avg. Vol
67,813
52-wk High
$8.25
52-wk Low
$2.35

Latest Key Developments (Source: Significant Developments)

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran
Thursday, 16 Nov 2017 01:39pm EST 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​.  Full Article

Arbutus Biopharma reports Q3 loss per share $0.21
Thursday, 2 Nov 2017 04:00pm EDT 

Nov 2 (Reuters) - Arbutus Biopharma Corp :Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results.Q3 non-GAAP loss per share $0.17.Q3 loss per share $0.21.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement
Wednesday, 18 Oct 2017 08:00am EDT 

Oct 18 (Reuters) - Arbutus Biopharma Corp : :Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients.Arbutus Biopharma Corp - is deploying proprietary lipid nanoparticle technology to deliver gritstone's rna-based neoantigen immunotherapy products​.Arbutus Biopharma - ‍under terms of license agreement, gritstone obtains worldwide access to arbutus' portfolio of proprietary and LNP products​.Arbutus Biopharma - ‍Gritstone will pay co upfront payment, payments for achievement of development, regulatory, and commercial milestones.  Full Article

Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Arbutus Biopharma Corp ::Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million.Intends to use proceeds from sale to further develop, advance its clinical, preclinical HBV pipeline programs.Roivant will invest preferred shares which will be convertible into common shares at conversion price of $7.13/share.Roivant has agreed to a four year lock‐up period for the preferred shares investment and its existing holdings in co.  Full Article

Arbutus announces topline results for ARB-1467 phase II Cohort 4
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Arbutus Biopharma Corp ::Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4.Arbutus Biopharma Corp - seven of the twelve patients met the predefined response criteria at or before day 71.Arbutus -initial results for monthly dosing extension suggest monthly dosing not sufficient to maintain/improve on reductions in s-antigen levels.Arbutus Biopharma - detailed results of cohort 4 are expected to be presented at AASLD in October.Arbutus Biopharma - planning to initiate new study of ARB-1467 in Q4 to evaluate longer dosing of ARB-1467 combined with Interferon.Arbutus Biopharma Corp - all 12 patients in cohort 4 experienced reductions in serum HBsAg levels.Arbutus Biopharma - to initiate new study in Q4 to study longer term Bi-weekly dosing of ARB-1467 in combination with Tenofovir.  Full Article

Arbutus Biopharma Q2 loss per share $0.33
Thursday, 3 Aug 2017 04:00pm EDT 

Aug 3 (Reuters) - Arbutus Biopharma Corp :Arbutus announces corporate update and second quarter 2017 financial results.Q2 non-gaap loss per share $0.28.Q2 loss per share $0.33.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Q2 revenue $1.0 million versus $300,000.Q2 revenue view $592,000 -- Thomson Reuters I/B/E/S.Arbutus Biopharma - ‍as at June 30, 2017, arbutus had cash, cash equivalents, short-term investments and restricted investments totaling $115.6 million.  Full Article

Arbutus announces conclusion of LNP license agreement with Alexion
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Arbutus Biopharma Corp :Arbutus announces conclusion of LNP license agreement with Alexion.Has received notice of termination from Alexion Pharmaceuticals Holding.Termination from Alexion Pharmaceuticals Holding for companies' LNP license agreement, which signed and announced in March 2017.Termination of agreement was driven by a strategic review of Alexion's business and research and development portfolio.  Full Article

RTW Investments LP reports 5 pct passive stake in Arbutus Biopharma
Wednesday, 17 May 2017 05:39pm EDT 

May 17 (Reuters) - Arbutus Biopharma Corp :RTW Investments LP reports 5.0 percent passive stake in Arbutus Biopharma Corp as of May 10 - SEC filing.  Full Article

Arbutus reports Q1 non-GAAP loss per share $0.29
Thursday, 4 May 2017 04:00pm EDT 

May 4 (Reuters) - Arbutus Biopharma Corp :Arbutus announces corporate update and first quarter 2017 financial results.Q1 non-GAAP loss per share $0.29.Q1 loss per share $0.34.Q1 revenue $200,000 versus $600,000.Q1 revenue view $3.1 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Arbutus Biopharma says Arbutus Injunction survives attempted appeal by Acuitas
Thursday, 13 Apr 2017 08:00am EDT 

Arbutus Biopharma Corp : Arbutus biopharma corp - arbutus injunction survives attempted appeal by acuitas . Arbutus biopharma corp - on march 7, 2017, acuitas appealed injunction decision and on april 3, 2017, appeal was denied .Arbutus biopharma corp - case regarding termination of acuitas' license from arbutus will be tried in court subject to scheduling.  Full Article

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran